anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-16. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
== Further reading == Cape Colony House of Assembly (1881). Copies of all Correspondence and Telegrams Having Reference to the Recent Rebellion. Saul Solomon & Co. Retrieved 7 January 2022. Lagden, Godfrey (1910). The Basutos: The Mountaineers & Their Country. Vol. II. Appleton. OCLC 908824713. Retrieved 7 January 2022. Sanders, Peter (2011). Throwing Down White Man: Cape Rule and Misrule in Colonial Lesotho, 1871–1884. Merlin Press. ISBN 978-0-850-36654-9. Tylden, G. (1969). "Basutoland Roll of Honour 1851 – 1881". Journal of the Society for Army Historical Research. 1 (5). ISSN 0026-4016. Retrieved 7 January 2022.
ribosomal DNA (rDNA) A DNA sequence that codes for ribosomal RNA (rRNA). In many eukaryotic genomes, rDNA occupies large, highly conserved regions of multiple chromosomes and is rich in both genes and repeats.
Particles such as whole cells or cell debris, which would clog a packed bed column, readily pass through a fluidized bed. EBA can therefore be used on crude culture broths or slurries of broken cells, thereby bypassing initial clearing steps such as centrifugation and filtration, which is mandatory when packed beds are used. In older EBA column designs, the feed flow rate is kept low enough that the solid packing remains stratified and does not fluidize completely. Hence EBA can be modelled as frontal adsorption in a packed bed, rather than as a well-mixed, continuous-flow adsorber.
Here, Cl is the total concentration of all polynucleotide chains belonging to a hypercycle Hl, C is the total concentration of polynucleotide chains belonging to all hypercycles, ql is the rate of growth, and φ is a dilution flux that guarantees that the total concentration is constant. According to the above model, in the initial phase, when several hypercycles exist, the selection of the hypercycle with the largest ql value takes place. When one hypercycle wins the selection and dominates the population, it is very difficult to replace it, even with a hypercycle with a much higher growth rate q.
Sources: en.wikipedia.org
=== Peru === Free Peru's leader Vladimir Cerrón denounced the US military action as an "imperialist war" and declared his solidarity with Venezuela. Popular Force's leader Keiko Fujimori called it a "historical event" marking the end of the "criminal dictatorship". Popular Renewal's leader Rafael López Aliaga praised the action and congratulated María Corina Machado.
Throughout the 1980s, estimates of illegal drug value in Colombia ranged from $2bn to $4bn. This made up about 7–10% of the $36bn estimated Gross National Product (GNP) of Colombia during this decade. In the 1990s, the estimates of the illegal drug value remained roughly within the same range (~$2.5bn). As the Colombian GNP rose throughout the 1990s ($68.5bn in 1994 and $96.3bn in 1997), illegal drug values began to comprise a decreasing fraction of the national economy. By the early 1990s, although Colombia led in the exportation of cocaine, it found increasing confrontations within its state. These confrontations were primarily between cartels and government institutions. This led to a decrease in the drug trade's contribution to the GDP of Colombia; dropping from 5.5% to 2.6%. Though a contributor of wealth, the distribution of cocaine has had negative effects on the socio-political situation of Colombia and has weakened its economy as well.
=== Other uses === 4-Nitrophenol is an intermediate in the synthesis of paracetamol. It is reduced to 4-aminophenol, then acetylated with acetic anhydride. 4-Nitrophenol is used as the precursor for the preparation of phenetidine and acetophenetidine, indicators, and raw materials for fungicides. Bioaccumulation of this compound rarely occurs. In peptide synthesis, carboxylate ester derivatives of 4-nitrophenol may serve as activated components for construction of amide moieties. In drug chemistry (medicine), 4-nitrophenol finds utility in the synthesis of fedratinib & glutaurine (protecting group).
Sources: en.wikipedia.org
During an exclusive interview with El Mundo on 5 June 2023, Kaili said, "I was not spied on with Pegasus, but for Pegasus, we believe Morocco, Spain, France and Belgium spied on the European Parliament's committee." In a statement to Politico, she said that Belgian secret services monitored her due to her work on the parliament's committee investigating the use of Pegasus spyware in Europe, claiming that this was the "real scandal". Revealed in Euro News article, it was mentioned that Belgian authorities tried to force her to name people in the case in exchange for "a deal". Furthermore, according to the Spanish activist and politician Miguel Urbán statement, the Qatargate scandal points to an even deeper Moroccogate affair. The European Parliament should take the same precautionary measures with Morocco as it did with Qatar. Every European Parliament legislative activity in recent years involving Moroccan interests should be retrospectively reviewed to ensure that it has not been influenced by foreign interference.
== Security == A wallet may have known and unknown vulnerabilities. A supply chain attack or side-channel attack are ways of introducing vulnerabilities. In extreme cases a computer which is not connected to any network can be hacked. To mitigate the risk of crypto wallet hacking, one can choose for a cold wallet, which remains offline and disconnected from the internet. A cold wallet refers to a physical device, such as a pen drive, that is utilized as a secure storage medium for transferring money from a hot wallet. Cold wallets have also been hacked. In late July 2026, cold wallet manufacturer Coinkite disclosed that a bug in software used on its devices allowed hackers to access cold wallets. This hack has lead to losses of approximately $130 million as of early August 2026.
Pulse chase assays are an alternative method to cycloheximide chase assays and involve the radioactive labeling of newly translated proteins followed by a similar "chase" period. While this method is informative and provides the benefit of observing nascent protein abundance, the radioactive material it requires is expensive with a shorter shelf-life and demands more caution to use than cycloheximide. Disadvantages Some disadvantages to conducting cycloheximide chase assays include the toxic nature of cycloheximide. When used at high concentrations over a long period of time, cycloheximide will damage the DNA within the cell and impair critical cellular function. For this reason, cycloheximide chases do not typically last for more than 12 hours. This presents a limitation if the turnover of a particularly stable protein is being studied. Additionally, cycloheximide chases only offer the ability to look at steady state proteins levels as opposed to newly translated protein levels such as with pulse chase. Therefore, only protein degradation and not protein maturation is able to be observed.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.